Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Seaman, D (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
07998974
ABSTRACT:
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic induced neuropathy, neuropathy associated with an ischemic event, polyglutamine diseases, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
REFERENCES:
patent: 2003/0134843 (2003-07-01), Lubisch et al.
patent: 2003/0144518 (2003-07-01), Chen
patent: 2007/0037752 (2007-02-01), Ansorge et al.
patent: 1 460 067 (2004-09-01), None
patent: WO-97/04766 (1997-02-01), None
patent: WO-99/33824 (1999-07-01), None
patent: WO-03/074516 (2003-09-01), None
patent: 2004035522 (2004-04-01), None
patent: WO-2005/026112 (2005-03-01), None
patent: WO-2005/037257 (2005-04-01), None
patent: WO 2006/076681 (2006-07-01), None
patent: WO 2006/105403 (2006-10-01), None
patent: WO-2006113458 (2006-10-01), None
patent: WO 2007/008548 (2007-01-01), None
patent: WO 2008/073451 (2008-06-01), None
Chen et al., Tetrahedron Letters (2001), 42(12), 2269-2271.
Varma et al., Journal of Heterocyclic Chemistry (1999), 36(6), 1565-1571.
Varma et al., Tetrahedron Letters (1999), 40(43), 7665-7669.
Blackburn et al., Tetrahedron Letters (1998), 39(22), 3635-3638.
Chavignon et al., Heterocycles (1995), 41(9), 2019-26.
Katritzky et al., Journal of Organic Chemistry (2000), 65(23), 8059-8062.
Sundberg et al., Journal of Medicinal Chemistry (1998), 41(22), 4317-4328.
Katsura et al., Chemical & Pharmaceutical Bulletin (1992), 40(7), 1818-22.
Denny et al., Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis (1990), 232(2), 233-41.
Winkelmann et al., Arzneimittel-Forschung (1977), 27(1), 82-9.
Saldabols et al., Khimiya Geterotsiklicheskikh Soedinenii (1973), (1), 137.
Zbiral et al., Tetrahedron Letters (1972), (5), 439-44.
Bienayme H. et al., “A New Heterocyclic Multicomponent Reaction for the Combinatorial Synthesis of Fused 3-Aminoimidazoles”,Angew. Chem. Int. Ed., vol. 37, No. 16, pp. 2234-2237 (1998).
Blackburn, Christopher, A Three-Component Solid-Phase Synthesis of 3-Aminoimidazo[1,2-a]azines,Tetrahedron Letters, vol. 39 pp. 5469-5472 (1998).
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 549524 XP002381647 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 7933104 XP002381648 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 537053 XP002381649 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 153431 XP002381650 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 207384 XP002381651 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 297282 XP002381652 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 792596 XP002381653 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 782709 XP002381654 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 7945513 XP002381655 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 619894 XP002381656 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 401890 XP002381657 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 528176 XP002381658 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 8428457 XP002381659 abstract.
Database Beilstein Crossfire, Beilstein Institute of Organic Chemistry; BRN: 210383 XP002381660 abstract.
Huang et al., “Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles”Bioorganic&Medicinal Chemistry, vol. 14 No. 17 pp. 6106-6119 (2006).
Porcu M. et al, “The Emerging Therapeutic Potential of Sirtuin-Interacting Drugs: From Cell Death to Lifespan Extension”,Trends in Pharmacological Sciences, vol. 26, No. 2, pp. 94-103 (2005).
Pacholec et al., “SRT1720, SRT2183 and SRT1460 Do Not Activate Sirt1 with Native Substrates”, FASEB Summer Research Conferences; NAD Metabolism and Signaling, Jun. 21-26, 2009.
Pacholec et al., “SRT1720, SRT2183, SRT1460, and Resveratrol are not Direct Activators of SIRT1”, JBC Papers in Press, Manuscript M109.088682, Jan. 8, 2010.
Pacholec et al., “SRT1720, SRT2183, SRT1460, and Resveratrol are not Direct Activators of SIRT1”, J. of Bio. Chem., 285(11):8340-8351, Mar. 12, 2010.
Papers of the Week, “A Resveratrol Reversal”, DOI 10.1074/jbc.P109.088682, Mar. 10, 2010 (abstract).
Baur et al., “Resveratrol improves health and survival of mice on a high-calorie diet”,Nature, 444(16):337-42 (2006).
Bitterman et al., “Inhibition of Silencing and Accelerated Aging by Nicotinamide, A67 a Putative Negative Regulator of Yeast Sir2 and Human SIRT1”,The J. of Bio. Chem. 277(47):46099-45107 (2002).
Chen et al., “SIRT1 Protects against Microglia-dependent Amyloid-Toxicity through Inhibiting NF-B Signaling”,The J. of Bio. Chem., 280(48):40364-74 (2005).
Ding et al., “Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells”,Pancreas, 25(4):71-76 (2002) (abstract only).
Jing et al., “Sirt2 Regulates Adipocyte Differentiation Involving FoxO1 Acetylation/ Deacetylation”,Cell Metab.. 6(2):105-14 (2007).
Liao et al., “Resveratrol Enhances Radiosensitivity of Human Non-Small Cell Lung Cancer NCI-H838 Cells Accompanied by Inhibition of Nuclear Factor-Kappa B Activiation”,J. Radiat. Res., 46:387-93 (2005).
Ma et al., “Resveratrol: A medical drug for acute pancreatitis”, World J. Gastroenterology, 11(21):3171-3174 (2005).
Parker et al., “Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons”,Nat. Genet, 37(4):349-50 (2005) (abstract).
Su et al., “Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats”,Am. J. Physiol. Endocrinol Metab, 290:E1339-46 (2006).
Bemis Jean
Milburn Michael
Milne Jill
Normington Karl D.
Nunes Joseph J.
Rahmani Niloofar
Ropes & Gray LLP
Seaman D
Sirtris Pharmaceuticals, Inc.
LandOfFree
Fused heterocyclic compounds and their use as sirtuin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterocyclic compounds and their use as sirtuin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds and their use as sirtuin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2693914